Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Therapy save search
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: -0.29%
H: 0.0%
C: 0.0%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
ATI Physical Therapy to Announce First Quarter 2024 Financial Results
Published: 2024-04-22 (Crawled : 16:00) - prnewswire.com
ATIP | News | $4.06 0.24% 0.0% 980
|
Manufacturing
|
| O: 3.23%
H: 2.64%
C: -2.16%
first financial therapy results
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI 4 d | $73.02 -1.34% -1.36% 730K
|
Health Technology
|
| O: 14.75%
H: 12.75%
C: 6.04%
positive topline therapy results study
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies—Poster will be unveiled this week at the Immunotherapy Conference in Munich
Published: 2024-03-21 (Crawled : 12:30) - biospace.com/
PHIO | News | $0.672 -4.0% -4.17% 91K
|
Health Technology
|
| O: -4.67%
H: 0.43%
C: -17.65%
conference cell pharmaceuticals immunotherapy week therapy
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Published: 2024-03-21 (Crawled : 12:00) - phiopharma.com
PHIO | News | $0.672 -4.0% -4.17% 91K
|
Health Technology
|
| O: -4.67%
H: 0.43%
C: -17.65%
cell pharmaceuticals therapy
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
ERNA | $1.8 -8.16% -8.89% 12K
|
Information
|
| O: 4.1%
H: 0.0%
C: -11.81%
LCTX | $1.1 -3.51% 0.0% 740K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -3.97%
rg6501 opregen innovation cell therapy results study
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
MDT | $80.38 -1.12% 0.0% 5M
|
Health Technology
|
| O: 0.15%
H: 1.26%
C: 0.97%
presentation favorable therapy results study
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA P | $0.376 -2.56% 64K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
PHIO | News | $0.672 -4.0% -4.17% 91K
|
Health Technology
|
| O: 2.25%
H: 15.0%
C: -1.0%
cell pharmaceuticals therapy
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.34%
H: 0.13%
C: -0.23%
yescarta fda t-cell change approval therapy
Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy
Published: 2023-11-22 (Crawled : 14:00) - globenewswire.com
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: 2.52%
H: 8.08%
C: 3.96%
elyxyb company care research potential migraine therapy results market
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
Published: 2023-10-30 (Crawled : 22:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 1.05%
H: 1.86%
C: -0.28%
global topline therapeutics duchenne therapy results study
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
Published: 2023-10-26 (Crawled : 21:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.05%
H: 0.01%
C: -2.17%
genetic therapy results
NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
NRXS | $2.96 4.97% 1.35% 16K
|
|
| O: -3.39%
H: 9.35%
C: 3.98%
disorders medical therapy results study
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
Published: 2023-09-11 (Crawled : 13:00) - prnewswire.com
SOMMY | $11.568 -9.46% 21K
|
Manufacturing
|
| O: 0.86%
H: 0.78%
C: 0.5%
pharma bladder positive topline therapy results
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
BCDA P | $0.376 -2.56% 64K
|
Health Technology
|
| O: -9.94%
H: 0.0%
C: -17.32%
cell cardiamp heart trial therapy results
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.31%
H: 1.04%
C: 0.76%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: -2.46%
H: 2.53%
C: -10.61%
berubicin pharmaceuticals therapy results study
Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS) in Sleep
Published: 2023-07-26 (Crawled : 17:00) - biospace.com/
PODD | $167.215 -0.03% -0.03% 650K
|
Health Technology
|
| O: -0.46%
H: 0.94%
C: 0.15%
health publication extension trial therapy results study
ATI Physical Therapy to Announce Second Quarter 2023 Financial Results
Published: 2023-07-24 (Crawled : 16:00) - prnewswire.com
ATIP | News | $4.06 0.24% 0.0% 980
|
Manufacturing
|
| O: 0.26%
H: 2.37%
C: -2.11%
financial therapy results
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
Published: 2023-06-15 (Crawled : 20:00) - globenewswire.com
MBIO | $0.35 -2.7% -2.77% 120K
|
Health Technology
|
| O: 2.33%
H: 8.95%
C: 6.95%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: 2.94%
H: 1.43%
C: 1.43%
mb-106 trial therapy results
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.